Brussels founders can reach regional equity, angel networks and European specialist investors without pretending they all serve the same company. The most useful shortlist starts with three questions: what the business has proved, which operating geography actually qualifies and what expertise the next milestone needs.
Compare 15 provider families, including 5 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Start with the company’s situation, not the size of the fund
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| A company with a meaningful Brussels-Capital operating connection | Research the appropriate finance&invest.brussels equity route. | Describe the local economic activity and product need. Do not substitute a loan or guarantee for the equity route. |
| An early Belgian B2B software company | Compare Seeder, Syndicate One, Volta, the relevant XAnge thesis and wider first-cheque capital. | Separate early product evidence from mature growth metrics and confirm geographic-origin criteria. |
| Healthcare, semiconductors or food-system innovation | Compare the relevant HERAN, imec.xpand, Capricorn or Astanor strategy. | Different scientific and regulatory development paths need different evidence; a sector label alone is not enough. |
| Defence or dual-use technology | Investigate Seven Capital’s current investment route. | Programme timing, direct funding and participation terms are separate decisions. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 15 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| finance&invest.brussels | Local / regional: Brussels-Capital Region; economic-value criteria | Startup, scale-up and SME routes | Multiple sectors; appropriate equity product required |
| BeAngels | Local / regional: Brussels office; Belgian and wider regional projects | Early-company and growth cases; investor-specific | Innovative businesses across sectors |
| Seeder Fund | Local / regional: Brussels office; Belgium and beyond | First financing rounds | Digital entrepreneurs |
| XAnge | Local / regional: Brussels, Paris and Berlin offices | Seed through Series B; strategy-specific | AI, deep tech, climate, health and vertical software |
| Seven Capital | Local / regional: Brussels base; European-sovereignty thesis | Early-stage routes; programme and direct investment differ | AI, autonomy, drones and cybersecurity |
| Syndicate One | Wider route: Belgian innovators; wider operator network | Pre-seed and seed | Technology companies |
| Astanor | Wider route: Europe and North America; strategy-specific | Separate seed, venture and growth strategies | Agriculture, food systems and enabling technology |
| 4Ventures | Wider route: Belgian investment platform; confirm company geography | Seed to Series A; current contact says no pre-seed | Software, hardware and other technology |
| Volta Ventures | Wider route: Companies originating in the Benelux | Pre-seed and seed | B2B software |
| Smartfin | Wider route: Companies headquartered in Europe | Growing companies; confirm entry round | B2B technology |
| Pitchdrive | Wider route: European founders; strategy-specific | Early rounds; confirm the current entry point | AI-native and technology businesses |
| imec.xpand | Wider route: Leuven-based specialist with international investing | Early technology and later development; confirm vehicle | Semiconductors, photonics and related deep tech |
| Capricorn Partners | Wider route: Europe with a Benelux focus | Fund-specific; separate venture and listed vehicles | Digital, health and clean technology |
| HERAN Partners | Wider route: Healthcare technology platform; confirm company geography | Company- and strategy-specific | Healthcare, life sciences and health technology |
| Seedcamp | Wider route: Europe, Israel or a distinctively European angle | Pre-product and pre-revenue through early revenue | Early technology companies |
Brussels, Flanders and Wallonia are not interchangeable eligibility labels
A Belgian address is not a universal pass to every region-linked investment vehicle. The Brussels-Capital Region’s explanation of finance&invest.brussels ties its role to businesses and economic value in the region. Other managers can have different geographic requirements.
Record where the company is registered, where the team operates and what the chosen vehicle actually requires. Where a condition is unclear, make that the first question. Do not invent a relocation plan or assume a future customer in Brussels satisfies a current operating requirement.
Choose the founder route, not the fund-investor route
Investor websites often serve two audiences: companies seeking investment and people considering investing in the fund. Use a founder pitch, financing enquiry or company submission route. An investor portal, LP contact or newsletter form is not the same thing.
The distinction also matters for angel networks. BeAngels helps select and prepare companies for investing members; it is not a promise that the network itself will write a cheque. Prepare the round, current evidence and the role you hope an angel can play. For a warm approach, give a potential introducer a specific reason that this company fits this investor.
What are the major venture capital firms in Belgium?
There is no single useful “major” list for every founder. This comparison includes early software investors, specialist science and food investors, a regional investment group and an angel network. For a national overview, use the Belgium investor guide. For a Brussels raise, prioritise the actual company-stage, regional and sector fit.
For example, Volta’s Benelux B2B software screen and HERAN’s healthcare focus change who should approach them. A larger platform or a more famous name does not resolve those differences. Build a shortlist you can explain, not a league table you cannot use.
15 investors and networks to research
1. finance&invest.brussels
Regional public-backed investment group. Regional relevance matters more than a Belgian postal address alone. finance&invest.brussels offers several forms of finance, including equity and lending. Identify the appropriate startup or scale-up route and explain the company’s activity and economic value in the Brussels-Capital Region. A loan product is not interchangeable with venture equity.
Approach: Use Demander un financement / the published financing enquiry. Official finance&invest.brussels information. Additional criteria or geographic context.
2. BeAngels
Angel-investor network. BeAngels connects companies to investing members. The network’s selection and preparation process is useful, but acceptance is not a pooled-fund commitment. Explain the current business evidence, round and why relevant angels could help. Its Brussels office supports a genuine local connection without making every member a Brussels-only investor.
Approach: Use the founder fundraising route, not investor membership. Official BeAngels information. Additional criteria or geographic context.
3. Seeder Fund
Early-stage technology venture fund. Seeder’s stated focus is early financing for digital businesses. A Brussels founder should make the initial buyer, product evidence and first financing milestone easy to understand. Use its founder pitch route rather than a general fund-investor enquiry; speed-of-decision marketing on a fund website should not be treated as an application-service guarantee.
Approach: Use Send your pitch. Official Seeder Fund information. Additional criteria or geographic context.
4. XAnge
European technology venture firm. XAnge combines a real Brussels office with a wider European mandate. Its current fund themes are more useful than the office address when deciding fit. A seed-stage AI productivity company and a scientific venture should explain different evidence, even when approaching the same firm. The founder portal is not the new-company pitch route.
Approach: Use Send your pitch. Official XAnge information. Additional criteria or geographic context.
5. Seven Capital
Dual-use and defence technology investor. Seven Capital adds a specialist Brussels route that a general country list can miss. Explain the actual defence or dual-use application and the team’s technical capability. Seven Camp is a time-bound programme with its own participation terms; do not confuse an accelerator application or completed cohort with an always-open direct-investment offer.
Approach: Use the investment Contact route; check cohort timing separately. Official Seven Capital information. Additional criteria or geographic context.
6. Syndicate One
Founder/operator seed investment firm. Syndicate One combines seed capital with experienced founders and operators in Belgium’s technology community. Its practical relevance is the operating problem a team needs help solving as well as the financing. Prepare a focused account of the company’s stage, the next milestone and why the network’s experience fits.
Approach: Use the official founder/contact information. Official Syndicate One information. Additional criteria or geographic context.
7. Astanor
Agrifood impact investment platform. Astanor’s food-system focus can fit a Brussels company, but its seed, venture and growth activities should not be collapsed into one entry stage. Explain the measurable operating change, the commercial buyer and the relevant financing milestone. Use the entrepreneur route rather than the separate investor-enquiry form.
Approach: Use the entrepreneur contact, not investor enquiries. Official Astanor information. Additional criteria or geographic context.
8. 4Ventures
Privately held venture fund. 4Ventures’ investment-scope text mentions occasional earlier investing, but its current contact section explicitly says no pre-seed. For this shortlist, treat seed and Series A as the practical starting screen. A founder should show the company’s actual maturity rather than relying on a historical or exceptional earlier deal.
Approach: Use the official Contact form. Official 4Ventures information.
9. Volta Ventures
B2B software venture firm. Volta makes both the business model and geographic-origin filter clear. A Brussels B2B software team should explain the business buyer and early product evidence, then establish the Benelux connection. Do not turn general European customer activity into a claim that the company satisfies the fund’s origin requirement.
Approach: Use the published Contact route. Official Volta Ventures information.
10. Smartfin
B2B technology investor. Smartfin’s current criteria focus on growing European B2B technology companies. A founder should explain the buyer, product advantage and commercial progress. The current criteria do not justify an assumption of idea-stage eligibility, so resolve the entry-round question before spending time on a detailed financing process.
Approach: Use Submit your pitch. Official Smartfin information.
11. Pitchdrive
Early-stage venture firm. Pitchdrive’s current activity includes a European AI-native fund and early technology rounds. For a Brussels founder, the useful task is to connect the company’s technical product with a credible customer problem and explain what the new round will prove. A portfolio funding headline is not a commitment to the same cheque or round structure.
Approach: Use the official founder/contact route. Official Pitchdrive information.
12. imec.xpand
Deep-tech venture investor. imec.xpand belongs in a semiconductor or science-led shortlist, not a general software mailout. Its current team describes technology feasibility and scale as core questions. Explain the technical bottleneck and potential role for imec-related expertise. An investor’s international portfolio does not remove the need to establish the particular company’s fit.
Approach: Use the published team/contact information. Official imec.xpand information. Additional criteria or geographic context.
13. Capricorn Partners
Technology venture investment manager. Capricorn manages different strategies across digital, health and clean technology. Select the relevant venture fund before approaching; the manager’s listed investment vehicle is not the same founder route. A useful first note explains the technical advantage, market and milestone in terms that fit the chosen strategy.
Approach: Use Submit your pitch. Official Capricorn Partners information.
14. HERAN Partners
Healthcare and life-sciences investor. HERAN’s specialist healthcare focus is a better screen than a broad Belgian-investor label. Explain the scientific or clinical problem, the evidence available and how the product reaches users or customers. Establish the appropriate development stage with the team instead of assuming all healthcare software, devices and therapeutics follow one investment process.
Approach: Use Submit your pitch. Official HERAN Partners information.
15. Seedcamp
First-cheque venture firm. Seedcamp’s FAQ explicitly includes companies before product and revenue as well as after launch. That gives a young team a clearer stage screen than an unqualified early-stage label. The company still needs a persuasive founder insight and scale of ambition. Its later support for existing companies is a separate matter.
Approach: Use Pitch Us, not a founder-community login. Official Seedcamp information.
A Brussels B2B software team makes an evidence-led shortlist
Fictional worked example. A fictional Brussels company sells workflow software to small professional-services teams. It has an MVP, three pilot users and one paying customer. It is raising its first institutional round, with no commitments yet. Its immediate job is to test repeatable adoption, not to claim product-market fit from a tiny sample.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| Volta / Seeder / Syndicate One | Compare the current early software thesis. | Document the company’s Belgian or Benelux connection and what the customer evidence demonstrates. |
| finance&invest.brussels | Investigate the appropriate regional equity route. | Explain the actual Brussels activity; do not assume every financing product suits a startup equity round. |
| 4Ventures | Resolve whether the company is ready for the stated seed focus. | The current contact page says no pre-seed, despite earlier-stage exceptions elsewhere on the site. |
| HERAN / imec.xpand / Seven Capital | Remove unless a genuine specialist fit exists. | General workflow software is not automatically healthcare, semiconductor or defence technology. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Brussels investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: BRUSSELS
Company, current evidence and next funding milestone: [authorised facts]
Regional facts: Brussels-Capital / Flanders / Wallonia / other
Company connection: registered office, operating activity and source
Thesis lane: B2B software / health / food / semiconductor / dual-use / other
Submission type: founder pitch / regional financing / angel selection / general enquiry
Programme window or sector requirement: confirmed / unknown / not relevant
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Brussels startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the Belgium investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 15 provider families are included: 5 documented local or regional routes and 10 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- Theodorus remains outside the counted list while current new-company investment availability is unresolved; an old portfolio or historic fund term is not enough.
- EU institutions and industry bodies are not counted as direct startup investors merely because they help finance the ecosystem.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.